RDAF 2022 General Assembly Meeting

    21 Mar, 2022

    On 21 March 2022, the Rare Disease Action Forum (RDAF) held its annual General Assembly meeting. An overview of the RDAF’s activities in 2021 and an outlook for 2022 were presented. The RDAF President welcomed the new members and underlined that the collaborative approach, which constitutes the core of the RDAF, is essential to identify barriers, raise awareness and work towards an improved framework for rare diseases.

    The General Assembly elected the RDAF Board of Directors: Shayesteh Fürst-Ladani (SFL Pharma), Jasmin Barman-Aksözen (Swiss Society for Porphyria), Rea Lal (Pfizer), Bettina Nauli (Alexion), Jacqueline de Sá (ProRaris), Alessandro Strebel (Roche), Andreas Uttenweiler (Takeda) and Raffaella Willmann (FSRMM). Shayesteh Fürst-Ladani was re-elected as RDAF President.

    Continue reading

    The RDAF publishes its newsletter

    The newsletter, which is published twice a year, gives an overview of all the Rare Disease Action Forum (RDAF) activities during the past half year to raise awareness about rare diseases in Switzerland and improve patient’s access to diagnosis, treatment and care....

    The RDAF joins the Rare Disease Day organized by ProRaris

    On 5 March 2022, the Rare Disease Action Forum (RDAF) will participate in the Swiss Rare Disease Day organized by the umbrella organization for patient organizations in the field of rare diseases, ProRaris. The RDAF is looking forward to hear the latest developments...